Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered
once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately
150 medically stable male and female subjects with clinical diagnoses of schizophrenia or
schizoaffective disorder with neuroleptic-induced TD or mood disorder with
neuroleptic-induced TD.